Needham & Company Reiterates a 'Buy' on MELA Sciences (MELA); Updating Earnings Model For Offering
Get Alerts MELA Hot Sheet
Price: $1.12 --0%
Rating Summary:
4 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
4 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company reiterates a 'Buy' on MELA Sciences (NASDAQ: MELA) price target of $20.00.
Needham analyst says, "On December 15, 2011 MELA offered 5 M shares in a registered offering, raising an anticipated net of $14.9 M to the company. This excludes 42,915 shares sold to the company’s CEO, Joseph Gulfo, and new board member, Robert Coradini, at $3.97 per share (the closing price of the shares on the date of the transaction). In this note, we update our earnings model for the impact of the offering, recap recent significant developments and reiterate our Buy."
"For 2016, which is the farthest our model currently forecasts, our revenue estimate is unchanged at $222.6 M. Based on higher dilution from the deal priced at $3.25 versus our assumption of $5.00, the EPS for that year is now $2.95 compared to our previous estimate of $3.15.(Needham raises FY12 EPS estimate from (0.90) to (0.82))
For an analyst ratings summary and ratings history on MELA Sciences click here. For more ratings news on MELA Sciences click here.
Shares of MELA Sciences closed at $3.42 yesterday.
Needham analyst says, "On December 15, 2011 MELA offered 5 M shares in a registered offering, raising an anticipated net of $14.9 M to the company. This excludes 42,915 shares sold to the company’s CEO, Joseph Gulfo, and new board member, Robert Coradini, at $3.97 per share (the closing price of the shares on the date of the transaction). In this note, we update our earnings model for the impact of the offering, recap recent significant developments and reiterate our Buy."
"For 2016, which is the farthest our model currently forecasts, our revenue estimate is unchanged at $222.6 M. Based on higher dilution from the deal priced at $3.25 versus our assumption of $5.00, the EPS for that year is now $2.95 compared to our previous estimate of $3.15.(Needham raises FY12 EPS estimate from (0.90) to (0.82))
For an analyst ratings summary and ratings history on MELA Sciences click here. For more ratings news on MELA Sciences click here.
Shares of MELA Sciences closed at $3.42 yesterday.
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Coherent (COHR) PT Raised to $420 at Needham
- Piper Sandler Reiterates Overweight Rating on KKR (KKR), 'highest conviction name'
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & Company, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share